You are here
Centers for Therapeutic Innovation
Translating Leading Science into Clinical Candidates Through Networked Collaboration
Overview — Reinventing Partnership
Launched in 2010, Pfizer’s Centers for Therapeutic Innovation (CTI) is a unique model for academic-industry collaboration, designed to bridge the gap between early scientific discovery and its translation into new medicines.
A key aspect of CTI is its local Centers in biomedical research hubs that enable Pfizer and academic teams to work side-by-side, blending the research expertise of academics in disease biology, targets, and patient populations with Pfizer’s developmental expertise and resources. This model represents a significant departure from the traditional lengthy and linear process of target discovery to eventual drug development. Pfizer funds pre-clinical and clinical development programs and offers equitable intellectual property and ownership rights and access to antibody libraries and other proprietary technologies.
With four locations in Boston, New York, San Diego, and San Francisco, CTI's open innovation model puts Pfizer scientists in the lab with academic investigators, where they share their understanding of target biology and translational medicine expertise. Pfizer provides access to select Pfizer compound libraries, proprietary screening methods, antibody development technologies, and a wealth of dedicated resources and support from Pfizer experts in drug development and protein sciences. The ultimate goal of each collaborative project is to validate a drug candidate that can be moved into further clinical testing.
CTI now has more than 23 academic institutions in its network, with a portfolio of projects across a variety of disease areas.